special aktie
Seite 1 von 1 Neuester Beitrag: 23.01.06 14:19 | ||||
| Eröffnet am: | 27.09.05 17:54 | von: skyline2004 | Anzahl Beiträge: | 23 |
| Neuester Beitrag: | 23.01.06 14:19 | von: skyline2004 | Leser gesamt: | 6.333 |
| Forum: | Hot-Stocks | Leser heute: | 3 | |
| Bewertet mit: |  | |||
&a=A0BL6V&zeitraum=6&bname=&save_presets=0&zoom.x=0&zeitvon=0&bis=1127835738&ind_adhoc=&zeitbis=&cookies=HASH(0x9c2eb54)&ind_volume=ON&von=0&go=upper&banner_ref=HASH(0x90a4b3c)&req_host=ARRAY(0x9682890)&b=0)
hier gibt es bald geld zu holen
Copyright 2005 World Markets Research Limited;
All Rights Reserved
World Markets Analysis
September 27, 2005
SECTION: IN BRIEF
LENGTH: 359 words
HEADLINE: Corgentech and AlgoRx Look Set to Merge
BYLINE: Jonathan Goodall
BODY: U.S. drug developer Corgentech Inc. and U.S. pharmaceutical company AlgoRx have announced they intend to merge in a share exchange deal between the two companies. As part of the deal, Corgentech has agreed to issue AlgoRx stock holders with Corgentech shares. AlgoRx stockholders will hold 62% of the shares in the newly formed company. The result of the merger will be a company with a pipeline of four clinical products focused on the areas of pain management and inflammation.
Significance: The merger between California-based Corgentech and New Jersey-based AlgoRx will not only form a company that has a good pipeline of promising clinical products but also the financial muscle - with US$124 million in cash, cash equivalents, and short-term investments - to progress some of those projects out of the clinic and into the approval stages. The most promising candidate to make this move is RX 3268, a topical local anaesthetic, which will become the merged company's most advanced clinical candidate. In a statement, Ronald M. Burch, AlgoRx's Chief Executive Officer, said it hoped to file a New Drug Application for ALGRX3268 at some point next year. The two companies intend to make a filing with the Securities and Exchange Commission over their planned merger in the next couple of weeks and a stockholders' vote on the merger is expected to take place either in December or early January. Earlier this year, Corgentech suffered a massive blow when its experimental vein graft prevention treatment, edifoligide, failed to meet its primary and secondary endpoints during its Phase III trial, leading to U.S. Bristol-Meyers Squibb terminating a co-development deal that it had with the company for the drug (see United States: 31 March 2005: Corgentech and BMS Lick Wounds After Vein Graft Drug Failure). This left Corgentech with a very lacklustre pipeline and a severely dented share price. Therefore, this latest announcement is the end of a chapter for Corgentech and as a newly merged company, it will have a bolstered pipeline that it will be able to use its development expertise on, to help move products towards the market.
LOAD-DATE: September 27, 2005
Auf jeden Fall momentan auf einem sehr attraktiven Niveau.
Sign In
New User?Sign Up
Finance Home - Help
Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
AP
AlgoRx, Corgentech Post Positive Data
Wednesday October 5, 8:20 am ET
AlgoRx, Corgentech Say Their Topical Anesthetic Reduced Needle-Prick Pain in Study
NEW YORK (AP) -- Biotech firms AlgoRx Pharmaceuticals Inc. and Corgentech Inc. said Wednesday that a late-stage study showed their experimental topical anesthetic significantly reduced the pain children felt from needle pricks, compared with a placebo.
Corgentech shares jumped 19 cents, or 8.3 percent, to $2.48 in recent premarket trading. Privately held AlgoRx of Secaucus, N.J., is in the process of acquiring South San Francisco, Calif.-based Corgentech in a stock swap deal.
The Phase III trial consisted of 574 patients ranging in age from three years to 18 years, who were undergoing procedures that required blood draws or intravenous line placements. The patients were given either the experimental ALGRX 3268 drug or a placebo.
AlgoRx and Corgentech added the drug started working in one to three minutes, substantially faster than traditional topical anesthetics, which can take up to an hour. The drug uses a powder-injection technology designed to accelerate permeation of the skin.
The companies plan to file an application with regulators seeking approval for the drug in the first half of 2006.
AlgoRx and Corgentech added the drug was well-tolerated and showed no significant safety issues.
Fundamental ein absolutes Schnäppchen. Notiert in einer Boombranche und DEUTLICH unter Buchwert zu haben im Moment.
Wednesday October 5, 7:00 am ET
Webcast Conference Call Scheduled for 8:30 a.m. EDT Today
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Oct. 5 /PRNewswire-FirstCall/ -- AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. (Nasdaq: CGTK - News) today announced positive data from the first of two ongoing Phase 3 trials of ALGRX 3268 -- a fast-acting local anesthetic administered into the skin by powder injection and aimed at reducing pain associated with venipuncture procedures (blood draws and intravenous line placements). The primary endpoint of the 574-pediatric patient trial was achieved showing that treatment with ALGRX 3268 demonstrated statistically significantly less pain (p=0.007) compared with the placebo group. ALGRX 3268 was well tolerated and demonstrated no significant safety issues.
ADVERTISEMENT
This study (003) was conducted at six centers in the United States in patients 3 to 18 years of age. A total of 574 patients were administered a placebo (285 patients) or the local anesthetic, ALGRX 3268 (289 patients) one to three minutes before having their procedures which required either venipuncture or intravenous cannulation. The primary endpoint was pain upon needle insertion utilizing the FACES pain scale. A second Phase 3 trial (004) of ALGRX 3268 with an identical clinical trial protocol is being conducted in approximately 500 patients, and data from this second pivotal trial are expected to be reported within two months.
"We are very pleased with the outcome of this study which shows that ALGRX 3268 is significantly more beneficial than any of the topical local anesthetics currently being offered on the market. Subjects who received ALGRX 3268 experienced less pain and onset was rapid, within one to three minutes compared to up to 60 minutes it takes for the most commonly used topical local anesthetics to offer analgesia," stated Ronald M. Burch, M.D., Ph.D., chief executive officer of AlgoRx. "Our plan is to file a new drug application (NDA) with the FDA for ALGRX 3268 during the first half of 2006."
"The clinical data from this trial of ALGRX 3268 are very strong, and we are focused on moving this product to market and expanding topical local anesthetic use with ALGRX 3268 in venipuncture procedures," said John P. McLaughlin, chief executive officer of Corgentech. "We are excited about the proposed merger of Corgentech and AlgoRx and believe that the combination will add measurable value for our stockholders by significantly bolstering our product pipeline and enabling us to more quickly move products into commercialization."
About ALGRX 3268 and the Market Opportunity for a Fast-Acting Local Anesthetic
ALGRX 3268 represents a near-term product opportunity for which an NDA is expected to be filed in the first half of 2006. The product is for local analgesia and is aimed at reducing the pain associated with venipunctures and intravenous line placements. ALGRX 3268 is based on a needleless injection system called Powderject®, which accelerates lidocaine particles, in powder form, into the epidermis in order to anesthetize nerves. The product, which may be especially useful in pediatric populations and emergency room settings, is easy to use and anesthetizes quickly -- generally in one minute -- offering an important advantage over currently available therapies.
The market for pain reduction with venipuncture procedures is an underserved market. Currently, in the largest children's hospitals and academic institutions in the United States, approximately 18 million venipuncture procedures occur each year. Of these 18 million procedures, topical local anesthetics are used in only 2.1 million of these procedures given that the currently marketed products require up to 60 minutes to offer benefit, compared with ALGRX 3268 which anesthetizes nerves within approximately one minute. With its fast onset-of-action, additional opportunities exist for ALGRX 3268 in the adult emergency room setting, hemodialysis and blood donation centers as well as physicians' offices and clinical laboratories.
About AlgoRx
AlgoRx is a private, emerging pharmaceutical company focused on developing and commercializing a diversified portfolio of pharmaceutical product candidates to address pain, a large and under-served market. AlgoRx's portfolio of pain management drug candidates includes ALGRX 3268, which is in Phase 3 clinical trials, ALGRX 4975, which is in Phase 2 clinical trials, and ALGRX 1207, which is soon to enter the clinic. AlgoRx is based in Secaucus, NJ. For more information on the company and its technologies, please visit www.algorx.com.
About Corgentech
Corgentech is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for significant unmet medical needs. Corgentech is based in South San Francisco, CA. For more information on the company and its technologies, please visit www.corgentech.com.
Webcast Conference Call Details
Corgentech will conduct a webcast conference call with the investment community at 8:30 a.m. EDT / 5:30 a.m. PDT, today, October 5, 2005 to discuss the clinical data. The call will be available via live audio broadcast over the Internet on the Corgentech website at www.corgentech.com. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by calling 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 1153884.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, clinical results forecasts of product development, FDA filings, benefits of the proposed merger, and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: whether the companies can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Corgentech's Form 10-K/A for the year ended December 31, 2004 and most recently filed Form 10-Q.
Corgentech and AlgoRx undertake no obligation and do not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.
Additional Information and Where to Find It
Corgentech Inc. intends to file a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. intend to file a related joint proxy statement/prospectus, in connection with the merger transaction involving Corgentech and AlgoRx. Investors and security holders are urged to read the registration statement on Form S-4 and the related joint proxy/prospectus when they become available because they will contain important information about the merger transaction. Investors and security holders may obtain free copies of these documents (when they are available) and other documents filed with the SEC at the SEC's web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by contacting Corgentech Investor Relations at the email address: investors@corgentech.com.
Corgentech, AlgoRx and their directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Corgentech and AlgoRx in connection with the merger transaction. Information regarding the special interests of these directors and executive officers in the merger transaction will be included in the joint proxy statement/prospectus of AlgoRx and Corgentech described above. Additional information regarding the directors and executive officers of Corgentech is also included in Corgentech's proxy statement for its 2005 Annual Meeting of Stockholders, which was filed with the SEC on April 27, 2005. This document is available free of charge at the SEC's web site at www.sec.gov and from Investor Relations at Corgentech as described above.
AlgoRx and Corgentech Announce Positive Phase 2 Data Demonstrating New Drug Significantly Reduces Foot Pain in Patients With Morton's Neuroma
10/18/05
Second Positive Clinical Results Report for Companies' Late-Stage Pain Products Pipeline in Two Weeks
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Oct 18, 2005 /PRNewswire-FirstCall via COMTEX/ --
AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. (Nasdaq: CGTK) today announced positive data from a Phase 2 trial of ALGRX 4975 in patients with Morton's neuroma-a painful neuropathy of the foot. In the 58-patient randomized, double-blind, placebo-controlled clinical trial, conducted at two study centers in the United States, the group consisting of 30 subjects who received ALGRX 4975 (100 micrograms) by a single injection into the neuroma had statistically significant decreases in their foot pain four weeks after the single administration of study drug. The mean baseline pain score (0-10 Numeric Rating Scale) was 5.7 for subjects in each treatment group. Pain scores were reduced at four weeks following the single administration of ALGRX 4975, with a mean pain score of 2.1 (63 percent reduction in pain) compared to 3.5 (38 percent reduction in pain) in subjects treated with placebo (p=0.0188). Additionally, ALGRX 4975 was well tolerated and did not demonstrate any significant safety issues.
"The strong pain relief demonstrated in this Phase 2 trial of ALGRX 4975 contributes to the growing body of data which demonstrate that this product candidate may be a safe and effective drug for a variety of moderate to severe pain syndromes," stated Ronald M. Burch, M.D., Ph.D., chief executive officer of AlgoRx. "ALGRX 4975 has been evaluated in more than 340 patients in several clinical trials across multiple post-surgical, neuropathic and musculoskeletal pain indications. In patients with moderate to severe pain, ALGRX 4975 has demonstrated significant pain relief, giving us confidence that this drug may have the potential to be used in many pain syndromes."
"We are pleased to report positive data from another product candidate in the pain management pipeline. This is the second set of good clinical trial data reported in less than two weeks, as we announced positive Phase 3 data from ALGRX 3268 earlier this month. This progress gives us additional confidence that our proposed merger with AlgoRx will increase the value of Corgentech for our stockholders as we continue to move decisively toward product commercialization," said John P. McLaughlin, chief executive officer of Corgentech. "We believe that ALGRX 4975 will have the ability to offer pain management benefits in a variety of post-surgical and other indications. The post-operative pain market in the United States alone is more than $1.7 billion, and we believe that there is an excellent opportunity for a safe and long-acting pain reliever which could reduce the need for opioid medications."
About ALGRX 4975 and the Market Opportunity for a Fast-Acting Local Anesthetic
ALGRX 4975, a VR1 agonist, is being developed for site-specific, moderate to severe pain. ALGRX 4975 is a C-neuron anesthetic, based on capsaicin. It is long-acting, providing pain relief to many patients for weeks or months after a single treatment. The product is administered locally at the site of pain and selectively reduces pain in nerve endings so does not affect other nerve fibers important for other sensory or motor skills. Phase 2 clinical trials are currently underway for post-surgical pain following a variety of surgeries including hernia repair, total knee replacement and cholecystectomy. In addition to the study for Morton's neuroma, a Phase 2 trial for another non-surgical procedure, tendonitis, is underway.
ALGRX 4975 has demonstrated its potential in multiple clinical studies to impact pain across neuropathic, post-surgical and musculoskeletal pain conditions. Opioid drugs, such as morphine, are used to service many of these conditions but are associated with significant side effects including respiratory depression, euphoria, and nausea and vomiting during acute use, and constipation and physical dependence during chronic use. ALGRX 4975 has not demonstrated similar side effects. Additionally, it has been shown that pain in the hospital is associated with increased length of stay, longer recovery times and poorer patient outcomes. By safely decreasing the patient's level of pain, ALGRX 4975 may have the potential to reduce a patient's length of hospital stay as well their need for opioids.
About Morton's Neuroma
Morton's neuroma is a painful condition of the foot that typically occurs as a result of wearing high narrow shoes, running, or spending considerable time standing each day. The thickening of the nerve tissue (neuroma) seems to occur in response to pressure or injury to one of the nerves that lead to the toes, resulting in pain and numbness that can make walking unbearable. Morton's neuroma is difficult to treat, so patients are often referred to foot specialists (podiatrists). In most patients, orthotics or analgesics such as aspirin-like drugs and opioids have limited effectiveness. More aggressive treatments, including surgical intervention to remove the nerve, are sometimes employed, but leave patients with permanent numbness in the foot.
About AlgoRx
AlgoRx is a private, emerging pharmaceutical company focused on developing and commercializing a diversified portfolio of pharmaceutical product candidates to address pain, a large and under-served market. AlgoRx's portfolio of pain management drug candidates includes ALGRX 3268, which is in Phase 3 clinical trials, ALGRX 4975, which is in Phase 2 clinical trials, and ALGRX 1207, which is soon to enter the clinic. AlgoRx is based in Secaucus, NJ. For more information on the company and its technologies, please visit www.algorx.com.
About Corgentech
Corgentech is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for significant unmet medical needs. Corgentech is based in South San Francisco, CA. For more information on the company and its technologies, please visit www.corgentech.com.
Webcast Analyst Meeting Details
Corgentech will conduct a webcast analyst meeting with the investment community in New York, NY at 12:00 p.m. EDT on Friday, October 21, 2005 to discuss clinical data, marketing opportunities and other information relating to ALGRX 3268, ALGRX 4975 and the rest of the company's product pipeline. The webcast will be available via live audio broadcast over the Internet on the Corgentech website at www.corgentech.com. A replay of the webcast will be available on the Corgentech website for at least two weeks following the meeting.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward- looking statements in this press release include, without limitation, clinical results forecasts of product development, FDA filings, benefits of the proposed merger, and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: whether the companies can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Corgentech's Form 10-K/A for the year ended December 31, 2004 and most recently filed Form 10-Q.
Corgentech and AlgoRx undertake no obligation and do not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.
Additional Information and Where to Find It
Corgentech Inc. intends to file a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. intend to file a related joint proxy statement/prospectus, in connection with the merger transaction involving Corgentech and AlgoRx. Investors and security holders are urged to read the registration statement on Form S-4 and the related joint proxy/prospectus when they become available because they will contain important information about the merger transaction. Investors and security holders may obtain free copies of these documents (when they are available) and other documents filed with the SEC at the SEC's web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by contacting Corgentech Investor Relations at the email address: investors@corgentech.com.
Corgentech, AlgoRx and their directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Corgentech and AlgoRx in connection with the merger transaction. Information regarding the special interests of these directors and executive officers in the merger transaction will be included in the joint proxy statement/prospectus of AlgoRx and Corgentech described above. Additional information regarding the directors and executive officers of Corgentech is also included in Corgentech's proxy statement for its 2005 Annual Meeting of Stockholders, which was filed with the SEC on April 27, 2005. This document is available free of charge at the SEC's web site at www.sec.gov and from Investor Relations at Corgentech as described above.
SOURCE Corgentech Inc.
investors, Jennifer Cook Williams of Corgentech Inc., +1-650-624-9600, or investors@corgentech.com; or media, Daryl Messinger of WeissComm Partners, +1-415-999-2361, or daryl@weisscommpartners.com, for Corgentech Inc. http://www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
10/19/05
SOUTH SAN FRANCISCO, Calif., Oct 19, 2005 /PRNewswire-FirstCall via COMTEX/ --
Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, will webcast an analyst meeting that it is hosting in New York, NY at 12 p.m. Eastern time on Friday, October 21, 2005 to discuss the combined product pipeline of Corgentech and AlgoRx Pharmaceuticals, Inc.
Interested parties can listen to the live audio webcast, or the subsequent archived recording, by logging on to www.corgentech.com and going to the Investor Information page. Please connect to Corgentech's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
About Corgentech
Corgentech is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for significant unmet medical needs. Corgentech and private company, AlgoRx Pharmaceuticals, Inc., recently announced that they have signed a definitive agreement to merge and create a late-stage company that will be largely focused on developing and commercializing products for pain management and inflammation. For more information on the company and its technologies, please visit www.corgentech.com.
SOURCE Corgentech Inc.
Jennifer Cook Williams, Senior Director, Investor Relations of Corgentech Inc., +1-650-624-9600, or investors@corgentech.com http://www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
Morgen übrigens Analystenkonferenz bei Corgentech. Die kontinuierlich steigenden Kurse lassen Gutes erahnen!
oder glaubst Du ernsthaft das sich einer dieses Kauderwelsch durchliest :-))).Sign In
New User?Sign Up
Finance Home - Help
Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Press Release Source: Corgentech Inc.
Corgentech Announces Management Promotions
Thursday January 19, 7:00 am ET
SOUTH SAN FRANCISCO, Calif., Jan. 19 /PRNewswire-FirstCall/ -- Corgentech Inc. (Nasdaq: CGTK - News) today announced the election of four individuals to vice president-level positions. The appointments include the promotions of Rolf O. Ehrhardt, M.D., Ph.D. to vice president, preclinical development; Melissa Morandi to vice president, quality assurance; Patricia Richards, M.D., Ph.D. to vice president, clinical research; and Jennifer Cook Williams to vice president, investor relations.
ADVERTISEMENT
"As we integrate our newly merged company and prepare for commercialization and further late-stage clinical development, it is key that we have the right team in place to achieve our goals, one of which includes filing a new drug application this year for our lead product candidate, ALGRX 3268," stated John P. McLaughlin, chief executive officer of Corgentech. "We have an executive team with a depth of experience in many critical areas including marketing and commercialization, clinical development and regulatory affairs and believe that Dr. Ehrhardt, Ms. Morandi, Dr. Richards and Ms. Williams will provide even further strength to our leadership team."
Rolf O. Ehrhardt, M.D. Ph.D., vice president of preclinical development, joined Corgentech in 2003 and most recently served as senior director, Inflammation in the research department. Dr. Ehrhardt has over 15 years of experience in drug development and translational science. Prior to joining Corgentech, he was the founding president of BioSeek, Inc., where he raised nearly $20 million in private financing rounds. Before that, Dr. Ehrhardt was at Protein Design Labs (now PDL BioPharma), where he led a scientific group focused on new target discovery/validation and development of immunotherapeutics. Prior to that, he was a Deutsche Forschungsgemeinschaft (DFG: German Research Foundation) and Fogarty fellow at the National Institutes of Health where his focus was on mucosal immunology and inflammatory bowel disease. He obtained his M.D. and Ph.D. with distinction from the Technical University of Munich, Germany.
Melissa Morandi, vice president of quality assurance, joined Corgentech in 2004 and most recently served as senior director of quality assurance drug and device. Prior to joining Corgentech, Ms. Morandi held director positions in Quality Assurance and Compliance at Biogen Idec Inc. Previously she spent nine years managing several different Quality departments at Genentech, Inc. and supported product launches and regulatory inspections for Genentech's oncology, cardiac and growth hormone products released during that timeframe. Prior to that, she worked at Amgen Inc. in Quality Assurance supporting product launches, new facility preparations for GMP approval, compliance auditing and lot release for Epogen® and Neupogen®. Before that, Ms. Morandi was employed by the Clinical Laboratory of Saint Francis Hospital, Santa Barbara and Ortho Diagnostics. She holds a B.A. degree from the University of California at Santa Barbara and a M.S. degree in Immunology from California State University at Northridge.
Patricia Richards, M.D., Ph.D., vice president of clinical research, joined Corgentech in December 2005 from AlgoRx Pharmaceuticals. Dr. Richards joined AlgoRx in 2004 where she led the Phase 3 clinical research program for ALGRX 3268 and the clinical research program for ALGRX 4975. From 2000 to 2004, Dr. Richards served as medical director for pain development programs at Purdue Pharma, a privately held pharmaceutical company. Prior to that, Dr. Richards was assistant professor of anesthesiology at New York University, serving as attending physician in the Pain Clinic and in the operating room, as well as working on clinical research programs for pain medications. Before that, Dr. Richards was director of the Pain Management Program at Piedmont and Northside Hospitals which followed her serving as assistant professor and a pain specialist at Johns Hopkins Hospital. Dr. Richards obtained a Ph.D. in pharmacology and an M.D. from the University of Chicago Pritzker School of Medicine and completed residencies in Internal Medicine and Anesthesiology and a fellowship in Pain Management at Johns Hopkins.
Jennifer Cook Williams, vice president of investor relations, joined Corgentech in 2004 and most recently served as senior director of investor relations. Ms. Williams is responsible for managing the corporate communications and investor relations functions at the company. Prior to joining Corgentech, she was with biotechnology company, Cell Genesys, Inc., for nearly 10 years where she most recently served as director of corporate communications and investor relations. Ms. Williams is on the investor relations advisory committee to the Biotechnology Industry Organization and has served on the board of the Silicon Valley Chapter of the National Investor Relations Institute (NIRI) since 2003. She holds a B.S. degree in Finance/Accounting from Central Washington University.
About Corgentech
Corgentech is a late-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management and inflammation. Corgentech is based in South San Francisco, CA. For more information on the company, please visit www.corgentech.com.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, projected timing of FDA filings and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: whether Corgentech can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Corgentech's Form S-4 as well as Corgentech's Form 10-K/A for the year ended December 31, 2004 and most recently filed Form 10-Q.
Corgentech undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.